Targeting Notch Signaling for Cancer Therapeutic Intervention

Hongwei Shao, Qinghua Huang, Zhao-Jun Liu

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

The Notch signaling pathway is an evolutionarily conserved, intercellular signaling cascade. The Notch proteins are single-pass receptors that are activated upon interaction with the Delta (or Delta-like) and Jagged/Serrate families of membrane-bound ligands. Association of ligand-receptor leads to proteolytic cleavages that liberate the Notch intracellular domain (NICD) from the plasma membrane. The NICD translocates to the nucleus, where it forms a complex with the DNA-binding protein CSL, displacing a histone deacetylase (HDAc)-corepressor (CoR) complex from CSL. Components of a transcriptional complex, such as MAML1 and histone acetyltransferases (HATs), are recruited to the NICD-CSL complex, leading to the transcriptional activation of Notch target genes. The Notch signaling pathway plays a critical role in cell fate decision, tissue patterning, morphogenesis, and is hence regarded as a developmental pathway. However, if this pathway goes awry, it contributes to cellular transformation and tumorigenesis. There is mounting evidence that this pathway is dysregulated in a variety of malignancies, and can behave as either an oncogene or a tumor suppressor depending upon cell context. This chapter highlights the current evidence for aberration of the Notch signaling pathway in a wide range of tumors from hematological cancers, such as leukemia and lymphoma, through to lung, skin, breast, pancreas, colon, prostate, ovarian, brain, and liver tumors. It proposes that the Notch signaling pathway may represent novel target for cancer therapeutic intervention.

Original languageEnglish
Pages (from-to)191-234
Number of pages44
JournalAdvances in Pharmacology
Volume65
DOIs
StatePublished - Sep 12 2012

Fingerprint

Neoplasms
Notch Receptors
Ligands
Therapeutics
Histone Acetyltransferases
Co-Repressor Proteins
Histone Deacetylases
DNA-Binding Proteins
Morphogenesis
Oncogenes
Brain Neoplasms
Transcriptional Activation
Prostate
Pancreas
Lymphoma
Colon
Carcinogenesis
Leukemia
Breast
Cell Membrane

Keywords

  • Cancer
  • Cancer therapeutics
  • Notch
  • Signal transduction
  • Tumor
  • Tumor angiogenesis

ASJC Scopus subject areas

  • Pharmacology

Cite this

Targeting Notch Signaling for Cancer Therapeutic Intervention. / Shao, Hongwei; Huang, Qinghua; Liu, Zhao-Jun.

In: Advances in Pharmacology, Vol. 65, 12.09.2012, p. 191-234.

Research output: Contribution to journalArticle

Shao, Hongwei ; Huang, Qinghua ; Liu, Zhao-Jun. / Targeting Notch Signaling for Cancer Therapeutic Intervention. In: Advances in Pharmacology. 2012 ; Vol. 65. pp. 191-234.
@article{bf84bb680dff42ea988f4546a6b27f58,
title = "Targeting Notch Signaling for Cancer Therapeutic Intervention",
abstract = "The Notch signaling pathway is an evolutionarily conserved, intercellular signaling cascade. The Notch proteins are single-pass receptors that are activated upon interaction with the Delta (or Delta-like) and Jagged/Serrate families of membrane-bound ligands. Association of ligand-receptor leads to proteolytic cleavages that liberate the Notch intracellular domain (NICD) from the plasma membrane. The NICD translocates to the nucleus, where it forms a complex with the DNA-binding protein CSL, displacing a histone deacetylase (HDAc)-corepressor (CoR) complex from CSL. Components of a transcriptional complex, such as MAML1 and histone acetyltransferases (HATs), are recruited to the NICD-CSL complex, leading to the transcriptional activation of Notch target genes. The Notch signaling pathway plays a critical role in cell fate decision, tissue patterning, morphogenesis, and is hence regarded as a developmental pathway. However, if this pathway goes awry, it contributes to cellular transformation and tumorigenesis. There is mounting evidence that this pathway is dysregulated in a variety of malignancies, and can behave as either an oncogene or a tumor suppressor depending upon cell context. This chapter highlights the current evidence for aberration of the Notch signaling pathway in a wide range of tumors from hematological cancers, such as leukemia and lymphoma, through to lung, skin, breast, pancreas, colon, prostate, ovarian, brain, and liver tumors. It proposes that the Notch signaling pathway may represent novel target for cancer therapeutic intervention.",
keywords = "Cancer, Cancer therapeutics, Notch, Signal transduction, Tumor, Tumor angiogenesis",
author = "Hongwei Shao and Qinghua Huang and Zhao-Jun Liu",
year = "2012",
month = "9",
day = "12",
doi = "10.1016/B978-0-12-397927-8.00007-5",
language = "English",
volume = "65",
pages = "191--234",
journal = "Advances in Pharmacology",
issn = "1054-3589",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Targeting Notch Signaling for Cancer Therapeutic Intervention

AU - Shao, Hongwei

AU - Huang, Qinghua

AU - Liu, Zhao-Jun

PY - 2012/9/12

Y1 - 2012/9/12

N2 - The Notch signaling pathway is an evolutionarily conserved, intercellular signaling cascade. The Notch proteins are single-pass receptors that are activated upon interaction with the Delta (or Delta-like) and Jagged/Serrate families of membrane-bound ligands. Association of ligand-receptor leads to proteolytic cleavages that liberate the Notch intracellular domain (NICD) from the plasma membrane. The NICD translocates to the nucleus, where it forms a complex with the DNA-binding protein CSL, displacing a histone deacetylase (HDAc)-corepressor (CoR) complex from CSL. Components of a transcriptional complex, such as MAML1 and histone acetyltransferases (HATs), are recruited to the NICD-CSL complex, leading to the transcriptional activation of Notch target genes. The Notch signaling pathway plays a critical role in cell fate decision, tissue patterning, morphogenesis, and is hence regarded as a developmental pathway. However, if this pathway goes awry, it contributes to cellular transformation and tumorigenesis. There is mounting evidence that this pathway is dysregulated in a variety of malignancies, and can behave as either an oncogene or a tumor suppressor depending upon cell context. This chapter highlights the current evidence for aberration of the Notch signaling pathway in a wide range of tumors from hematological cancers, such as leukemia and lymphoma, through to lung, skin, breast, pancreas, colon, prostate, ovarian, brain, and liver tumors. It proposes that the Notch signaling pathway may represent novel target for cancer therapeutic intervention.

AB - The Notch signaling pathway is an evolutionarily conserved, intercellular signaling cascade. The Notch proteins are single-pass receptors that are activated upon interaction with the Delta (or Delta-like) and Jagged/Serrate families of membrane-bound ligands. Association of ligand-receptor leads to proteolytic cleavages that liberate the Notch intracellular domain (NICD) from the plasma membrane. The NICD translocates to the nucleus, where it forms a complex with the DNA-binding protein CSL, displacing a histone deacetylase (HDAc)-corepressor (CoR) complex from CSL. Components of a transcriptional complex, such as MAML1 and histone acetyltransferases (HATs), are recruited to the NICD-CSL complex, leading to the transcriptional activation of Notch target genes. The Notch signaling pathway plays a critical role in cell fate decision, tissue patterning, morphogenesis, and is hence regarded as a developmental pathway. However, if this pathway goes awry, it contributes to cellular transformation and tumorigenesis. There is mounting evidence that this pathway is dysregulated in a variety of malignancies, and can behave as either an oncogene or a tumor suppressor depending upon cell context. This chapter highlights the current evidence for aberration of the Notch signaling pathway in a wide range of tumors from hematological cancers, such as leukemia and lymphoma, through to lung, skin, breast, pancreas, colon, prostate, ovarian, brain, and liver tumors. It proposes that the Notch signaling pathway may represent novel target for cancer therapeutic intervention.

KW - Cancer

KW - Cancer therapeutics

KW - Notch

KW - Signal transduction

KW - Tumor

KW - Tumor angiogenesis

UR - http://www.scopus.com/inward/record.url?scp=84865858012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865858012&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-397927-8.00007-5

DO - 10.1016/B978-0-12-397927-8.00007-5

M3 - Article

C2 - 22959027

AN - SCOPUS:84865858012

VL - 65

SP - 191

EP - 234

JO - Advances in Pharmacology

JF - Advances in Pharmacology

SN - 1054-3589

ER -